ICH E9 emphasizes the importance of transparent and comprehensive reporting of trial results. This includes detailed descriptions of the statistical methods used, the presentation of both primary and secondary outcomes, and a discussion of the limitations. For cancer trials, clear reporting is essential to understand the clinical significance of the findings and to facilitate meta-analyses and systematic reviews.
